Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes

In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML). Join us as we dive into the essential aspects of CML treatment, including: The importance of initial workup and bone marrow biopsy in diagnosing CML. ⁠Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib. ⁠Patient-centered decision-making and how to align treatment options with individual patient goals. ⁠Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD). ⁠The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities. ⁠Insights into the role of transplant in accelerated and blast phases of CML. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights. #CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes